The Punch on MSN13 天
Stem cell therapy: Breakthrough for repairing corneas, restoring sight
Stem cell therapy has emerged as a groundbreaking treatment option for corneal injuries, offering hope to individuals ...
Ophthalmology Times9 天
Stem cell-based CALEC therapy achieves 90% corneal surface restoration in clinical trial
The study evaluated 14 patients that were treated with cultivated autologous limbal epithelial cells (CALEC) and followed ...
‘Irreversible’ eye damage fixed by stem cells in human trial
Researchers successfully pulled off the first eye stem cell transplants to help heal cornea damage, and the results speak for ...
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy ...
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease ...
Study finds eye injury previously thought irreversible was cured in human trials
The study was led by Harvard Medical School and Massachusetts Eye and Ear researchers and surgeons. The researchers reported ...
BioPharma Dive2 天
Alcon buys majority stake in IPO-seeking cell therapy startup Aurion
The share acquisition is the latest twist in a dispute between Alcon and fellow Aurion shareholder Deerfield Management over ...
Ophthalmology Times2 天
Alcon acquires majority interest in Aurion Biotech
Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal ...
Morningstar3 天
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy ...
Aurion will operate as a separate company with full support from Alcon to advance its clinical-stage allogeneic cell therapy asset, AURN001, into Phase 3 for corneal edema secondary to corneal ...